Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Among authors: wiendl h. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Monoclonal antibodies in neuroinflammatory diseases.
Klotz L, Wiendl H. Klotz L, et al. Among authors: wiendl h. Expert Opin Biol Ther. 2013 Jun;13(6):831-46. doi: 10.1517/14712598.2013.767329. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23521026 Review.
Rasmussen encephalitis treated with natalizumab.
Bittner S, Simon OJ, Göbel K, Bien CG, Meuth SG, Wiendl H. Bittner S, et al. Among authors: wiendl h. Neurology. 2013 Jul 23;81(4):395-7. doi: 10.1212/WNL.0b013e31829c5ceb. Epub 2013 Jun 21. Neurology. 2013. PMID: 23794679 No abstract available.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: wiendl h. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
New evidence for teriflunomide in multiple sclerosis.
Kieseier BC, Wiendl H. Kieseier BC, et al. Among authors: wiendl h. Lancet Neurol. 2014 Mar;13(3):234-5. doi: 10.1016/S1474-4422(14)70012-2. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461573 No abstract available.
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group. Giacomini PS, et al. N Engl J Med. 2014 Jan 30;370(5):486-8. doi: 10.1056/NEJMc1304828. N Engl J Med. 2014. PMID: 24476450 Free PMC article. No abstract available.
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators. Butzkueven H, et al. Among authors: wiendl h. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14. J Neurol Neurosurg Psychiatry. 2014. PMID: 24532785 Free PMC article. Clinical Trial.
722 results